The Effect of the Severity of COVID-19 Disease on the Incidence of Acute Renal Failure in ICU

COVID19 Clinical Trial

Official title:

The Effect of the Severity of COVID-19 Disease on the Incidence of Acute Renal Failure in ICU

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04799600
• Other study ID #: E1-20-1443
• Status: Completed
• Start date: September 1, 2020
• Est. completion date: July 1, 2021

Study information

• Verified date: July 2021
• Source: Ankara City Hospital Bilkent
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Aim of the study is to determinate the frequency of acute renal failure in COVID-19 patients, its relationship with the severity of COVID-19 disease in ICU, and the ability to take precautions against these factors.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 158
• Est. completion date: July 1, 2021
• Est. primary completion date: June 15, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

Patients hospitalized in the intensive care unit diagnosed with COVID-19 will include in the study.

Exclusion Criteria:

there is no exclusion criteria

Related Conditions & MeSH terms

• Acute Kidney Injury
• Acute Renal Failure
• COVID19
• Renal Insufficiency

Intervention

Other:
• BRESCIA-COVID Respiratory Severity Scale
KDIGO acute renal failure score BRESCIA-COVID Respiratory Severity Score

Locations

Country	Name	City	State
Turkey	Ankara City Hospital	Ankara

Sponsors (1)

Lead Sponsor	Collaborator
Ankara City Hospital Bilkent

Country where clinical trial is conducted

Turkey, 

References & Publications (3)

Kellum JA, Lameire N; KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care. 2013 Feb 4;17(1):204. doi: 10.1186/cc11454. Review. — View Citation

Rodriguez-Nava G, Yanez-Bello MA, Trelles-Garcia DP, Chung CW, Friedman HJ, Hines DW. Performance of the quick COVID-19 severity index and the Brescia-COVID respiratory severity scale in hospitalized patients with COVID-19 in a community hospital setting. — View Citation

Wang L, Li X, Chen H, Yan S, Li D, Li Y, Gong Z. Coronavirus Disease 19 Infection Does Not Result in Acute Kidney Injury: An Analysis of 116 Hospitalized Patients from Wuhan, China. Am J Nephrol. 2020;51(5):343-348. doi: 10.1159/000507471. Epub 2020 Mar 3 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	KDIGO criteria	KDIGO Criteria stage 1: Increase in SCr by = 0.3 mg/dL within 48 hours or increase in SCr 1.5 to 1.9 times baseline which is known or presumed to have occurred within the prior 7 days Stage 2: 2.0 to 2.9 multiplied by baseline SCr; Stage 3: 3.0 or more multiplied by baseline; increase in SCr = 4.0 mg/dL; or beginning of renal replacement therapy regardless of a previous KDIGO stage.	6 months
Primary	BRESCIA-COVID RESPIRATORY SEVERITY SCALE (BCRSS) scores	The BCRSS score (between level 0-8) is calculated from "www.mdcalc.com/brescia-covid-respiratory-severity-scale-bcrss-algorithm" according to the severity of COVID disease , respiratory rate, PaO2 level, chest x-ray, and clinical status.	6 months